Characterization of complement receptor 1 domains for prevention of complement-mediated red cell destruction

Transfusion

Volumn 45, Issue 2, 2005, Pages 234-244

  Mqadmi, Amina ^a   Abdullah, Yazan ^a   Yazdanbakhsh, Karina ^a  

^a NEW YORK BLOOD CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3B RECEPTOR; MUTANT PROTEIN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DESTRUCTION; COMPLEMENT ACTIVATION; CONTROLLED STUDY; ERYTHROCYTE LIFESPAN; ERYTHROCYTE TRANSFUSION; FEMALE; GENE DELETION; HEMOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; MOUSE; NONHUMAN; PROTEIN DOMAIN; SITE DIRECTED MUTAGENESIS; STRUCTURE ACTIVITY RELATION;

ANIMALS; BINDING SITES; BLOOD TRANSFUSION; COMPLEMENT INACTIVATOR PROTEINS; ERYTHROCYTES; FEMALE; HEMOLYSIS; HUMANS; LIGANDS; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, SCID; MUTAGENESIS, SITE-DIRECTED; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, COMPLEMENT 3B;

EID: 13144303521     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2004.04163.x     Document Type: Article

References (32)

1. Ahearn JM, Fearon DT. Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21). Adv Immunol 1989;46:183-219.
2. Iida K, Nussenzweig V. Complement receptor is an inhibitor of the complement cascade. J Exp Med 1981;153:1138-50.
3. Fearon DT. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane. Proc Natl Acad Sci U S A 1979;76:5867-71.
4. Cooper NR. Immune adherence by the fourth component of complement. Science 1969;165:396-8.
5. Medof ME, Iida K, Mold C, et al. Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes. J Exp Med 1982;156:1739-54.
6. Klickstein LB, Wong WW, Smith JA, et al. Human C3b/C4b receptor (CR1): demonstration of long homologous repeating domains that are composed of the short consensus repeats characteristics of C3/C4 binding proteins. J Exp Med 1987;165:1095-112.
7. Hourcade D, Miesner DR, Atkinson JP, et al. Identification of an alternative polyadenylation site in the human C3b/C4b receptor (complement receptor type 1) transcriptional unit and prediction of a secreted form of complement receptor type 1. J Exp Med 1988;168:1255-70.
8. Klickstein LB, Bartow TJ, Miletic V, et al. Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis. J Exp Med 1988;168:1699-717.
9. Krych M, Hourcade D, Atkinson JP. Sites within the complement C3b/C4b receptor important for the specificity of ligand binding. Proc Natl Acad Sci U S A 1991;88:4353-7.
10. Kalli KR, Hsu PH, Bartow TJ, et al. Mapping of the C3b-binding site of CR1 and construction of a (CR1)2-F (ab′)2 chimeric complement inhibitor. J Exp Med 1991;174:1451-60.
11. Krych M, Clemenza L, Howdeshell D, et al. Analysis of the functional domains of complement receptor type 1 (C3b/C4b receptor; CD35) by substitution mutagenesis. J Biol Chem 1994;269:13273-8.
12. Krych M, Hauhart R, Atkinson JP. Structure-function analysis of the active sites of complement receptor type 1. J Biol Chem 1998;273:8623-9.
13. Krych-Goldberg M, Hauhart RE, Subramanian VB, et al. Decay accelerating activity of complement receptor type 1 (CD35): two active sites are required for dissociating C5 convertases. J Biol Chem 1999;274:31160-8.
14. Reilly BD, Makrides SC, Ford PJ, et al. Quantitative analysis of C4b dimer binding to distinct sites on the C3b/C4b receptor (CR1). J Biol Chem 1994;269:7696-701.
15. Makrides SC, Scesney SM, Ford PJ, et al. Cell surface expression of the C3b/C4b receptor (CR1) protects Chinese hamster ovary cells from lysis by human complement. J Biol Chem 1992;267:24754-61.
16. Petz LD, Garratty G. Acquired immune hemolytic anemias. New York: Churchill Livingstone; 1980.
17. Sazama K. Reports of 355 transfusion-associated deaths: 1976 through 1985. Transfusion 1990;30:583-90.
18. Schreiber AD, Frank MM. Role of antibody and complement in the immune clearance and destruction of erythrocytes. II. Molecular nature of IgG and IgM complement-fixing sites and effects of their interaction with serum. J Clin Invest 1972;51:583-9.
19. Makrides SC. Therapeutic inhibition of the complement system. Pharmacol Rev 1998;50:59-87.
20. Zimmerman JL, Dellinger RP, Straube RC, et al. Phase I trial of the recombinant soluble complement receptor 1 in acute lung injury and acute respiratory distress syndrome. Crit Care Med 2000;28:3149-54.
21. Rioux P. TP-10 (AVANT immunotherapeutics). Curr Opin Investig Drugs 2001;2:364-71.
22. Li JS, Sanders SP, Perry AE, et al. Pharmacokinetics and safety of TP10, soluble complement receptor 1, in infants undergoing cardiopulmonary bypass. Am Heart J 2004;147:173-80.
23. Yazdanbakhsh K, Kang S, Tamasauskas D, et al. Complement receptor 1 inhibitors for prevention of immune-mediated red cell destruction: potential use in transfusion therapy. Blood 2003;101:5046-52.
24. Tamasauskas D, Powell V, Schawalder A, et al. Localization of Knops system antigens in the long homologous repeats (LHRs) of complement receptor 1. Transfusion 2001;41:1397-404.
25. Issitt PD. Applied blood group serology. 3rd ed. Miami: Montgomery Scientific Publications; 1985.
26. Ish C, Ong GL, Desai N, et al. The specificity of alternative complement pathway-mediated lysis of erythrocytes: a survey of complement and target cells from 25 species. Scand J Immunol 1993;38:113-22.
27. Shultz LD, Schweitzer PA, Christianson SW, et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol 1995;154:180-91.
28. Capon DJ, Chamow SM, Mordenti J, et al. Designing CD4 immunoadhesins for AIDS therapy. Nature 1989;337:525-31.
29. Scesney SM, Makrides SC, Gosselin ML, et al. A soluble deletion mutant of the human complement receptor type 1, which lacks the C4b binding site, is a selective inhibitor of the alternative complement pathway. Eur J Immunol 1996;26:1729-35.
30. Mulligan MS, Warner RL, Rittershaus CW, et al. Endothelial targeting and enhanced antiinflammatory effects of complement inhibitors possessing sialyl Lewisx moieties. J Immunol 1999;162:4952-9.
31. Fischer MB, Ma M, Goerg S, et al. Regulation of the B cell response to T-dependent antigens by classical pathway complement. J Immunol 1996;157:549-56.
32. Smith BO, Mallin RL, Krych-Goldberg M, et al. Structure of the C3b binding site of CR1 (CD35), the immune adherence receptor. Cell 2002;108:769-80.